CellTraffix Technology Separates Adult Stem Cells From Bone Marrow Print E-mail
Potential for New Stem Cell Collection Platform

Rochester, NY, November 29, 2007— Using a microtube device coated with the protein P-selectin, researchers have isolated and collected adult stem cells residing in human bone marrow to eight times greater purity than can be obtained through traditional centrifugation, CLINICAL CHEMISTRY reported in the current issue (http://www.clinchem.org/cgi/content/abstract/clinchem.2007.089896).  This new proprietary technique, which is less costly and easier to use than current procedures, has been demonstrated to capture a significant quantity of viable hematopoietic stem and progenitor cells (HSPCs) from bone marrow in an in-vitro setting.

“This is the first published demonstration that selectins can be used to enrich CD34+ stem cells,” commented Dr. Michael King, Associate Professor, Biomedical Engineering and Chemical Engineering at the University of Rochester, and a leading expert in cell binding and flow dynamics.  Dr. King’s lab conducted the research.  “This shows that a flow-based model may constitute a new and more effective way to capture and purify the stem cells in bone marrow, and has implications for cell separation in the blood stream.  Now that we have altered a plastic microtube to resemble the bone marrow environment and sequestered adult stem cells within the device, we are trying to create microenvironments that lure metastatic cancer cells out of the blood stream.”

CellTraffix Inc. holds the exclusive worldwide right to commercialize Dr. King’s novel approach to using selectins for flow-mediated separation of target cells in the blood stream.  “These results validate the science behind the CellTraffix technology.  It is our intention to develop a range of medical devices based upon it,” commented Thomas Fitzgerald, CEO of CellTraffix Inc.  “There is a significant commercial opportunity to develop research kits, analytical tools, diagnostic agents, and therapeutic delivery systems utilizing Dr. King’s work on the separation and enrichment of adult stem cells”

About the Study

Dr. Jane Liesveld (University of Rochester) extracted the human bone marrow (HBM) from the pelvic area of willing donors.  The HBM was centrifuged, and then run through tubing internally coated with either P-selectin, an antibody against CD34, or a non-adhesive control protein.  While cell capture on control surfaces was negligible, P-selectin-coated surfaces showed appreciable capture of HSPCs, which increased with P-selectin concentration.  Researchers were able to achieve a 6-8-fold enrichment of the HSPCs with the P-selectin-coated devices.  Moreover, captured cells were viable and exhibited the ability to expand into cell-producing colonies, a key characteristic for stem cell transplantation.  Dr. Joel Wojciechowski (CellTraffix), Dr. Srinivas Narasipura, and Nichola Charles (University of Rochester) performed the groundbreaking flow experiments.

HSPCs have carbohydrate ligands on their surface which have the ability to adhere to specific proteins.  When they are perfused through a microtube coated with P-selectin, they roll along the surface wall and accumulate in large numbers that can be collected.  These adult stem cells, which are found in the bone marrow, are crucial in the formation of new blood cells, and therefore constitute a potentially rich transplantation source for hematological disorders.

About CellTraffix

CellTraffix employs its unique understanding of the mechanics of cellular flow and cell trafficking in the blood stream to develop a range of proprietary medical devices for research kits, diagnostics, analytical devices, and therapeutic delivery systems to address a number of unmet medical needs relating to cancer, adult stem cells and immune cells.

CellTraffix has established strategic relationships with the University of Rochester, as well as MIT, to advance the Company’s core technologies.

Company Contact:
Thomas Fitzgerald
President and CEO
(585) 267-4840

Media Relations:
Deanne Eagle
Cameron Associates
(212) 554-5463
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it